Skip to main content

Advertisement

SpringerLink
Log in

Cyclin D1 and cyclin E2 are differentially expressed in gastric cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Cell cycle regulators cyclin D1 and cyclin E2 function in G1/S transition by activating downstream cyclin-dependent kinases. Deregulated expression of these cyclins has been reported in various cancers. However, little is known about their clinical significance in gastric carcinoma. We aimed to explore that whether there is differential expression of these cyclins in clinically distinct gastric cancer patients. In this study we recruited a total of 92 subjects including 20 controls and 72 cases of histopathologically proven gastric carcinoma. Expression profiling at transcript level was done by semiquantitative RT-PCR and of protein by immunohistochemistry. Receiver operator characteristics analysis was done for determining diagnostic utility of cyclin D1 and cyclin E2. We demonstrate that cyclins D1 and E2 are frequently overexpressed in early stages of gastric carcinoma. Interestingly, expression of cyclins D1 and E2 significantly correlates with different clinical parameters such as gender, histological type (intestinal and diffuse), tumor location (proximal, middle, and distal), tumor differentiation (differentiated and undifferentiated), tumor invasion (serosal, lymphatic, and venous) and tumor metastasis (lymph node, peritoneal, ascites, and liver). Cyclin D1 has significantly higher sensitivity and specificity as diagnostic biomarker than cyclin E2. Our results suggest that overexpression of cyclin D1 and cyclin E2 is an early event in gastric carcinogenesis. The differential expression of these cyclins may be useful as diagnostic biomarkers for early detection of gastric carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Ferlay J, Forman D, Mathers CD. Bray Breast and cervical cancer in 187 countries between 1980 and 2010. Lancet F. 2012;379(12):1390–401.

    Article  CAS  Google Scholar 

  2. Dikshit RP, Nagrani R, Yeole B, Koyande S, Banawali S. Changing trends of chronic myeloid leukemia in greater Mumbai, India over a period of 30 years. Indian J Med Paediatr Oncol. 2011;32(2):96–100.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol. 2003;14(2):31–6.

    Google Scholar 

  4. Konturek PC, Konturek SJ, Brzozowski T. Gastric cancer and Helicobacter pylori infection. J Physiol Pharmacol. 2006;57(3):51–65.

    Google Scholar 

  5. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.

    Article  CAS  PubMed  Google Scholar 

  6. Grivenikov SI, Greten FR, Karin M. Immunity, Inflammation and cancer. Cell. 2010;140(6):883–99.

    Article  Google Scholar 

  7. Sherr CJ, Roberts JM. Cdk inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13(12):1501–12.

    Article  CAS  PubMed  Google Scholar 

  8. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin dependent kinases. Genes Dev. 2004;18(22):2699–711.

    Article  CAS  PubMed  Google Scholar 

  9. Weinberg RA. The Retinoblastoma protein and cell cycle control. Cell. 1995;81(3):323–30.

    Article  CAS  PubMed  Google Scholar 

  10. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 1998;12(15):2245–562.

    Article  CAS  PubMed  Google Scholar 

  11. Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell. 1994;79(4):573–82.

    Article  CAS  PubMed  Google Scholar 

  12. Xiong Y, Zhang H, Beach D. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell. 1992;71(3):505–14.

    Article  CAS  PubMed  Google Scholar 

  13. Riabowol K, Draetta G, Brizuela L, Vandre D, Beach D. The cdc2 kinase is a nuclear protein that is essential for mitosis in mammalian cells. Cell. 1989;57(3):393–401.

    Article  CAS  PubMed  Google Scholar 

  14. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 1996;68:67–108.

    Article  CAS  PubMed  Google Scholar 

  15. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003;36(3):131–49.

    Article  CAS  PubMed  Google Scholar 

  16. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene. 2006;25(11):1620–8.

    Article  CAS  PubMed  Google Scholar 

  17. Musgrove EA. Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors. 2006;24(1):13–9.

    Article  CAS  PubMed  Google Scholar 

  18. Yamamoto M, Tamakawa S, Yoshie M, Yaginuma Y, Ogawa K. Neoplastic hepatocyte growth associated with cyclin D1 redistribution from the cytoplasm to the nucleus in mouse hepatocarcinogenesis. Mol Carcinog. 2006;45(12):901–13.

    Article  CAS  PubMed  Google Scholar 

  19. Wang C, Li Z, Fu M, Bouras T, Pestell RG. Signal transduction mediated by cyclin D1: from mitogens to cell proliferation: a molecular target with therapeutic potential. Cancer Treat Res. 2004;119:217–37.

    Article  CAS  PubMed  Google Scholar 

  20. Stacey DW. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol. 2003;15(2):158–63.

    Article  CAS  PubMed  Google Scholar 

  21. Chung DC. Cyclin D1 in human neuroendocrine: tumorigenesis. Ann NY Acad Sci. 2004;1014:209–17.

    Article  CAS  PubMed  Google Scholar 

  22. Shoker BS, Jarvis C, Davies MP, Iqbal M, Sibson DR, Sloane JP. Immunodetectable cyclin D1 is associated with oestrogen receptor but not Ki67 in normal, cancerous and precancerous breast lesions. Br J Cancer. 2001;84(8):1064–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Ahn MJ, Kim BH, Jang SJ, Hong EK, Lee WM, Baik HK, et al. Expression of cyclin D1 and cyclin E in human gastric carcinoma and its clinicopathologic significance. J Korean Med Sci. 1998;13(5):513–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Tahara E, Semba S, Tahara H. Molecular biological observations in gastric cancer. Semin Oncol. 1996;23(3):307–15.

    CAS  PubMed  Google Scholar 

  25. Kaufmann WK, Kaufman DG. Cell cycle control, DNA repair and initiation of carcinogenesis. FASEB J. 1993;7(12):1188–91.

    CAS  PubMed  Google Scholar 

  26. Schraml P, Bucher C, Bissig H, Nocito A, Haas P, Wilber K, et al. Cyclin E overexpression and amplification in human tumours. J Pathol. 2003;200(3):375–82.

    Article  CAS  PubMed  Google Scholar 

  27. Donnellan R, Kleinschmidt I, Chetty R. Cyclin E immunoexpression in breast ductal carcinoma: pathologic correlations and prognostic implications. Hum Pathol. 2001;32(1):89–94.

    Article  CAS  PubMed  Google Scholar 

  28. Tissier F, Louvel A, Grabar S, Hagnéré AM, Bertherat J, Vacher-Lavenu MC. Cyclin E correlates with malignancy and adverse prognosis in adrenocortical tumors. Eur J Endocrinol. 2004;150(6):809–17.

    Article  CAS  PubMed  Google Scholar 

  29. Kamai T, Takagi K, Asami H, Ito Y, Oshima H, Yoshida KI. Decreasing of p27(Kip1) and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer. Br J Cancer. 2001;84(9):1242–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Takano Y, Kato Y, van Diest PJ, Masuda M, Mitomi H, Okayasu I. Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol. 2000;156(2):585–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Aoyagi K, Koufuji K, Yano S, Murakami N, Terasaki Y, Yamasaki Y. Immunohistochemical study on the expression of cyclin D1 and E in gastric cancer. Kurume Med J. 2000;47(3):199–203.

    Article  CAS  PubMed  Google Scholar 

  32. Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL. Cyclooxygenase-2 overexpressed in human cervical cancer. Clin Cancer Res. 2001;7(2):429–34.

    CAS  PubMed  Google Scholar 

  33. Jordan S, Lidhar K, Korbonits M, Lowe DG, Grossman AB. Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur J Endocrinol. 2000;143(1):R1–6.

    Article  CAS  PubMed  Google Scholar 

  34. Turner HE, Nagy Z, Sullivan N, Esiri MM, Wass JA. Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland. Clin Endocrinol. 2000;53(3):337–44.

    Article  CAS  Google Scholar 

  35. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer. 2007;7(10):750–62.

    Article  CAS  PubMed  Google Scholar 

  36. Jin M, Inoue S, Umemura T, Moriya J, Arakawa M, Nagashima K, et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer. 2001;34(2):207–18.

    Article  CAS  PubMed  Google Scholar 

  37. Barnes DM, Gillett CE. Cyclin D1 in breast cancer. Breast Cancer Res Treat. 1998;52(1–3):1–15.

    Article  CAS  PubMed  Google Scholar 

  38. Barkova EN, Gurov OV. Daily dynamics of the duration of hexenal narcosis in experimental hepatosis. Biull Eksp Biol Med. 1995;119(5):540–3.

    Article  CAS  PubMed  Google Scholar 

  39. Shamma A, Doki Y, Shiozaki H, Tsujinaka T, Yamamoto M, Inoue M. Cyclin D1 overexpression in esophageal dysplasia: a possible biomarker for carcinogenesis of esophageal squamous cell carcinoma. Int J Oncol. 2000;16(2):261–6.

    CAS  PubMed  Google Scholar 

  40. Myung N, Kim MR, Chung IP, Kim H, Jang JJ. Loss of p16 and p27 is associated with progression of human gastric cancer. Cancer Lett. 2000;153(1–2):129–36.

    Article  CAS  PubMed  Google Scholar 

  41. Gao P, Zhou GY, Liu Y, Li JS, Zhen JH, Yuan YP. Alteration of cyclin D1 in gastric carcinoma and its clinicopathologic significance. World J Gastroenterol. 2004;10(20):2936–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Jeanmart M, Lantuejoul S, Fievet F, Moro D, Sturm N, Brambilla C. Value of immunohistochemical markers in preinvasive bronchial lesions in risk assessment of lung cancer. Clin Cancer Res. 2003;9(6):2195–203.

    CAS  PubMed  Google Scholar 

  43. Mauro L, Pellegrino M, Giordano F, Ricchio E, Rizza P, De Amicis F. Estrogen receptor-α drives adiponectin effects on cyclin D1 expression in breast cancer cells. FASEB J. 2015;29(5):2150–60.

    Article  CAS  PubMed  Google Scholar 

  44. Naidu R, Wahab NA, Yadav MM, Kutty MK. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters. Oncol Rep. 2002;9(2):409–16.

    CAS  PubMed  Google Scholar 

  45. Sezer E, Böer-Auer A, Cetin E, Tokat F, Durmaz E, Sahin S. Diagnostic utility of Ki-67 and Cyclin D1 immunostaining in differentiation of psoriasis vs. other psoriasiform dermatitis. Dermatol Pract Concept. 2015;5(3):7–13.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Melck A, Masoudi H, Griffith OL, Rajput A, Wilkins G, Bugis S. Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer. Ann Surg Oncol. 2007;14(12):3403–11.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Authors acknowledge financial assistance from Department of Biotechnology (DBT), Ministry of Science and Technology, India, to Dr. Puneet (BT/PR/11113/10/678/2008); Banaras Hindu University for financial assistance to Dr. Sunita Singh; Soni Kumari is thankful to DBT and Banaras Hindu University for Junior Research Fellowships.

Funding

This study was funded by Department of Biotechnology, Government of India, vide Grant number BT/PR11113/BRB/10/678/2008 to Dr. Puneet and financial assistance from Banaras Hindu University to Dr. Sunita Singh and Soni Kumari.

Author information

Author notes

  1. Shyam Babu Prasad

    Present address: Department of Microbiology, Central University of Rajasthan, Kishangarh, 305 801, India

Authors and Affiliations

  1. Cancer Genetics Laboratory, Department of Molecular and Human Genetics, Banaras Hindu University, Varanasi, 221 005, India

    Soni Kumari, Shyam Babu Prasad, Suresh Singh Yadav & Gopeshwar Narayan

  2. Department of General Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221 005, India

    Puneet & A. Khanna

  3. Applied Molecular Biology Laboratory, School of Life Sciences, Jawaharlal Nehru University, New Delhi, 110 067, India

    Suresh Singh Yadav

  4. Department of Pathology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221 005, India

    Mohan Kumar

  5. Department of Gastroenterology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221 005, India

    V. K. Dixit

  6. Department of Microbiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221 005, India

    Gopal Nath

  7. Department of Zoology, Mahila Mahavidyalaya, Banaras Hindu University, Varanasi, 221 005, India

    Sunita Singh

Authors
  1. Soni Kumari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Puneet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shyam Babu Prasad
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Suresh Singh Yadav
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohan Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Khanna
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. V. K. Dixit
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gopal Nath
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sunita Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Gopeshwar Narayan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gopeshwar Narayan.

Ethics declarations

Conflict of interest

Authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki Declaration ethical standards and approved by the Institutional Ethical Committee of Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. The study was approved by the Institutional Ethical Committee of Institute of Medical Sciences, Banaras Hindu University.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kumari, S., Puneet, Prasad, S.B. et al. Cyclin D1 and cyclin E2 are differentially expressed in gastric cancer. Med Oncol 33, 40 (2016). https://doi.org/10.1007/s12032-016-0754-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-016-0754-8

Keywords

Search

Navigation